The SGLT2 inhibitors were originally developed to treat glycaemia in people with type 2 diabetes however there is now a wealth of evidence to demonstrate their significant cardio renal benefits that are quite separate from their glycaemic effectiveness. These drugs are now being prescribed increasingly for people with and without diabetes who have evidence of chronic kidney disease and/or heart failure. All clinicians need to feel confident that they understand the indications for these agents and how to use them safely. In this session I will be taking the audience through the March 2023 updated national guidelines on the use of SGLT2 inhibitors in people kidney disease which will cover the subject comprehensively including indications for prescription and how to use these agents appropriately